Nicholas J Reynolds

List of Publications by Year
in descending order

143 papers	7,344 citations	53751 45 h-index	60583 81 g-index
151 all docs	151 docs citations	151 times ranked	6943 citing authors

#	Article	IF	Citations
1	Anakinra for palmoplantar pustulosis: results from a randomized, doubleâ€blind, multicentre, twoâ€staged, adaptive placeboâ€controlled trial (APRICOT)*. British Journal of Dermatology, 2022, 186, 245-256.	1.4	22
2	Differences in Clinical Features and Comorbid Burden between HLA-Câˆ—06:02 Carrier Groups in >9,000 People with Psoriasis. Journal of Investigative Dermatology, 2022, 142, 1617-1628.e10.	0.3	11
3	Training and Retaining Physicianâ€“Scientists in Dermatology: A United Kingdom Perspective. JID Innovations, 2022, 2, 100091.	1.2	1
4	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. Efficacy and Mechanism Evaluation, 2022, 9, 1-106.	0.9	1
5	Cutaneous manifestations of acute kidney injury. CKJ: Clinical Kidney Journal, 2022, 15, 855-864.	1.4	1
6	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology, 2022, 150, 882-893.	1.5	21
7	Research Techniques Made Simple: Analysis of Autophagy in the Skin. Journal of Investigative Dermatology, 2021, 141, 5-9.e1.	0.3	7
8	Developmental cell programs are co-opted in inflammatory skin disease. Science, 2021, 371, .	6.0	264
9	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e498-e501.	1.3	2
10	Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. British Journal of Dermatology, 2021, 185, 203-205.	1.4	3
11	Therapeutic wavelengths of ultraviolet B radiation activate apoptotic, circadian rhythm, redox signalling and key canonical pathways in psoriatic epidermis. Redox Biology, 2021, 41, 101924.	3.9	10
12	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e496-e498.	1.3	4
13	Defining trajectories of response in patients with psoriasis treated with biologic therapies. British Journal of Dermatology, 2021, 185, 825-835.	1.4	4
14	Dominant effect of gap junction communication in woundâ€induced calciumâ€wave, NFAT activation and wound closure in keratinocytes. Journal of Cellular Physiology, 2021, 236, 8171-8183.	2.0	6
15	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. Journal of Investigative Dermatology, 2021, 141, 1872-1878.	0.3	4
16	Enhanced NF-Î°B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications, 2021, 12, 4741.	5.8	23
17	The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2250-2258.	1.3	9
18	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. JAMA Dermatology, 2021, 157, 66.	2.0	14

#	Article	IF	Citations
19	Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas. British Journal of Dermatology, 2020, 182, 156-165.	1.4	16
20	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 769-778.	1.3	27
21	Psoriasis treat to target: defining outcomes in psoriasis using data from a realâ€world, populationâ€based cohort study (the British Association of Dermatologists Biologics and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	3.4	88
22	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. American Journal of Human Genetics, 2020, 107, 539-543.	2.6	44
23	The History and Future Prospects of ISID: A European Perspective. Journal of Investigative Dermatology, 2020, 140, S178-S180.	0.3	0
24	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatology, 2020, 156, 1216.	2.0	18
25	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 2020, 183, 294-302.	1.4	85
26	microRNAâ€184 is induced by storeâ€operated calcium entry and regulates early keratinocyte differentiation. Journal of Cellular Physiology, 2020, 235, 6854-6861.	2.0	5
27	Using Realâ€World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokineticâ€Pharmacodynamic Study. Clinical and Translational Science, 2020, 13, 400-409.	1.5	9
28	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 2020, 140, 2129-2137.	0.3	6
29	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 2020, 21, 158.	0.7	7
30	Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2020, 96, 19-24.	1.0	6
31	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (<scp>BADBIR</scp>). British Journal of Dermatology, 2019, 180, 329-337.	1.4	36
32	Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. British Journal of Dermatology, 2019, 180, 195-196.	1.4	31
33	Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 2019, 143, 1021-1026.	1.5	165
34	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatology, 2019, 155, 1235.	2.0	30
35	IL-17 May Be a Key Cytokine Linking Psoriasis and Hyperglycemia. Journal of Investigative Dermatology, 2019, 139, 1214-1216.	0.3	9
36	Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy. British Journal of Dermatology, 2019, 181, 1138-1145.	1.4	22

#	Article	IF	Citations
37	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2019, 143, 2120-2130.	1.5	128
38	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 2019, 180, 1069-1076.	1.4	74
39	Human and computational models of atopic dermatitis: AÂreview and perspectives by an expert panel of the International Eczema Council. Journal of Allergy and Clinical Immunology, 2019, 143, 36-45.	1.5	58
40	Defining the Therapeutic Range for AdalimumabÂand Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. Journal of Investigative Dermatology, 2019, 139, 115-123.	0.3	60
41	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 2019, 180, 894-901.	1.4	12
42	Persistence and effectiveness of nonbiologic systemic therapies for moderateâ€toâ€severe psoriasis in adults: a systematic review. British Journal of Dermatology, 2019, 181, 256-264.	1.4	14
43	The devil is in the data: differences in drug persistence between <scp>SNIIRAM</scp> , the French national health insurance database, and psoriasis biologics intervention registers. British Journal of Dermatology, 2019, 180, 8-10.	1.4	2
44	A Framework for Multi-Omic Prediction ofÂTreatment Response to Biologic TherapyÂfor Psoriasis. Journal of Investigative Dermatology, 2019, 139, 100-107.	0.3	30
45	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 775-784.	0.3	71
46	An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema. British Journal of Dermatology, 2018, 179, 63-71.	1.4	22
47	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: AÂProspective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 534-541.	0.3	62
48	Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patientsâ€™ Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 2018, 138, 785-794.	0.3	48
49	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials, 2018, 19, 465.	0.7	15
50	Response to â€œComment on: â€˜When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Councilâ€™â€•. Journal of the American Academy of Dermatology, 2018, 79, e25-e26.	0.6	1
51	PD-1 regulates KLRG1+ group 2 innate lymphoid cells. Journal of Experimental Medicine, 2017, 214, 1663-1678.	4.2	163
52	Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema. Journal of Allergy and Clinical Immunology, 2017, 140, 1299-1309.	1.5	46
53	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology, 2017, 177, 1410-1421.	1.4	24
54	High prevalence of alcohol use disorders in patients with inflammatory skin diseases. British Journal of Dermatology, 2017, 177, 837-844.	1.4	24

#	Article	IF	Citations
55	Doxycycline: a first-line treatment for bullous pemphigoid?. Lancet, The, 2017, 389, 1586-1588.	6.3	9
56	Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. British Journal of Dermatology, 2017, 176, 1617-1623.	1.4	31
57	Ustekinumab for severe atopic dermatitis: an important negative study. British Journal of Dermatology, 2017, 177, 339-341.	1.4	5
58	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	0.6	170
59	Increasing Comorbidities Suggest that Atopic DermatitisÂIsÂaÂSystemic Disorder. Journal of Investigative Dermatology, 2017, 137, 18-25.	0.3	283
60	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 2017, 176, 1297-1307.	1.4	50
61	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 2017, 26, 4301-4313.	1.4	41
62	Kidney disease in moderate-to-severe psoriasis: a critical appraisal. British Journal of Dermatology, 2016, 174, 267-270.	1.4	8
63	<scp>CARD</scp> 14 mutations may predict response to antitumour necrosis factorâ€Î± therapy in psoriasis: a potential further step towards personalized medicine. British Journal of Dermatology, 2016, 175, 17-18.	1.4	3
64	Translating translation into patient benefit for atopic eczema. British Journal of Dermatology, 2016, 175, 8-12.	1.4	4
65	What does the BJD now stand for? A position statement. British Journal of Dermatology, 2015, 172, 1463-1465.	1.4	16
66	Demographics and disease characteristics of patients with psoriasis enrolled in the <scp>B</scp> ritish <scp>A</scp> ssociation of <scp>D</scp> ermatologists <scp>B</scp> iologic <scp>I</scp> nterventions <scp>R</scp> egister. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87
67	Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise. British Journal of Dermatology, 2015, 173, 1191-1198.	1.4	12
68	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.3	318
69	Establishing an Academicâ€“Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology, 2015, 135, 2903-2907.	0.3	30
70	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. Arthritis Care and Research, 2014, 66, 1410-1416.	1.5	21
71	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. British Journal of Dermatology, 2014, 170, 995-996.	1.4	0
72	One hundred and twenty-five years and counting: into an era of systems dermatology. British Journal of Dermatology, 2014, 171, 1279-1281.	1.4	4

#	Article	IF	Citations
73	Induction of a chloracne phenotype in an epidermal equivalent model by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on aryl hydrocarbon receptor activation and is not reproduced by aryl hydrocarbon receptor knock down. Journal of Dermatological Science, 2014, 73, 10-22.	1.0	25
74	Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. Journal of Allergy and Clinical Immunology, 2013, 132, 1121-1129.	1.5	135
75	The c-Rel Subunit of NF-îºB Regulates Epidermal Homeostasis and Promotes Skin Fibrosis in Mice. American Journal of Pathology, 2013, 182, 2109-2120.	1.9	34
76	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	130
77	Penicillin to Prevent Recurrent Leg Cellulitis. New England Journal of Medicine, 2013, 368, 1695-1703.	13.9	149
78	Predicting response to anti-interleukin 12/23 treatment in psoriasis. British Journal of Dermatology, 2013, 169, 240-241.	1.4	0
79	Lysophosphatidic Acid Promotes Cell Migration through STIM1- and Orai1-Mediated Ca 2+ i Mobilization and NFAT2 Activation. Journal of Investigative Dermatology, 2013, 133, 793-802.	0.3	30
80	Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. British Journal of Dermatology, 2012, 166, 7-11.	1.4	8
81	The British Association of Dermatologistsâ€™ Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology, 2012, 166, 545-554.	1.4	108
82	Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.6	23
83	Spectral effects of UV on psoriasis. Photochemical and Photobiological Sciences, 2012, 12, 47-53.	1.6	32
84	Measuring disease activity and damage in cutaneous lupus erythematosus. British Journal of Dermatology, 2011, 164, 221-222.	1.4	1
85	British Association of Dermatologistsâ€™ guidelines for the safe and effective prescribing of azathioprine 2011. British Journal of Dermatology, 2011, 165, 711-734.	1.4	107
86	Keratinocyte Secretion of Cyclophilin B via the Constitutive Pathway Is Regulated through Its Cyclosporin-Binding Site. Journal of Investigative Dermatology, 2011, 131, 1085-1094.	0.3	20
87	Keratinocyte Apoptosis in Epidermal Remodeling and Clearance of Psoriasis Induced by UV Radiation. Journal of Investigative Dermatology, 2011, 131, 1916-1926.	0.3	90
88	Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. Journal of Investigative Dermatology, 2011, 131, 1981-1986.	0.3	84
89	Measuring disease activity and damage in discoid lupus erythematosus. British Journal of Dermatology, 2010, 162, 1030-1037.	1.4	19
90	Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. British Journal of Dermatology, 2009, 161, 884-889.	1.4	98

#	Article	IF	Citations
91	British Association of Dermatologistsâ€™ guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology, 2009, 161, 987-1019.	1.4	412
92	Prevalent and Low-Frequency Null Mutations in the Filaggrin Gene Are Associated with Early-Onset and Persistent Atopic Eczema. Journal of Investigative Dermatology, 2008, 128, 1591-1594.	0.3	95
93	Filaggrin null mutations and childhood atopic eczema: A population-based case-control study. Journal of Allergy and Clinical Immunology, 2008, 121, 940-946.e3.	1.5	143
94	Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. Journal of Allergy and Clinical Immunology, 2008, 122, 560-568.e4.	1.5	83
95	Management of psoriasis in pregnancy. BMJ: British Medical Journal, 2007, 334, 1218-1220.	2.4	61
96	Eczema in pregnancy. BMJ: British Medical Journal, 2007, 335, 152-154.	2.4	48
97	Agonist-induced calcium entry correlates with STIM1 translocation. Journal of Cellular Physiology, 2007, 211, 569-576.	2.0	31
98	Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg. Trials, 2007, 8, 3.	0.7	8
99	Null Mutations in the Filaggrin Gene (FLG) Determine Major Susceptibility to Early-Onset Atopic Dermatitis that Persists into Adulthood. Journal of Investigative Dermatology, 2007, 127, 564-567.	0.3	298
100	An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. British Journal of Dermatology, 2007, 156, 346-351.	1.4	153
101	Increased nuclear Î²-catenin in suprabasal involved psoriatic epidermis. British Journal of Dermatology, 2007, 157, 1168-1177.	1.4	43
102	Inhibition of calcium-independent phospholipase A impairs agonist-induced calcium entry in keratinocytes. British Journal of Dermatology, 2007, 158, 071119222739009-???.	1.4	4
103	Elevated Expression and Genetic Association Links the SOCS3 Gene to Atopic Dermatitis. American Journal of Human Genetics, 2006, 78, 1060-1065.	2.6	47
104	Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet, The, 2006, 367, 839-846.	6.3	259
105	An Ancient Malady. American Journal of Medicine, 2006, 119, 1039-1042.	0.6	0
106	Use of topical glycopyrrolate in Ross syndrome. Journal of the American Academy of Dermatology, 2006, 55, S111-S112.	0.6	12
107	Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation. British Journal of Dermatology, 2006, 154, 194-195.	1.4	16
108	Atopic and non-atopic eczema. BMJ: British Medical Journal, 2006, 332, 584-588.	2.4	81

#	Article	IF	Citations
109	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology, 2005, 153, 486-497.	1.4	245
110	Absence of Association Between Asthma and High Serum Immunoglobulin E Associated GPRA Haplotypes and Adult Atopic Dermatitis. Journal of Investigative Dermatology, 2005, 125, 399-401.	0.3	23
111	The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB Journal, 2005, 19, 1012-1014.	0.2	97
112	Guidelines for prescribing azathioprine in dermatology. British Journal of Dermatology, 2004, 151, 1123-1132.	1.4	120
113	Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. British Journal of Dermatology, 2003, 149, 1259-1265.	1.4	29
114	Phototherapy and systemic treatments. British Journal of Hospital Medicine, 2002, 63, 657-661.	0.3	0
115	Localization of Calcineurin/NFAT in Human Skin and Psoriasis and Inhibition of Calcineurin/NFAT Activation in Human Keratinocytes by Cyclosporin A. Journal of Investigative Dermatology, 2002, 118, 779-788.	0.3	136
116	Calcineurin-Hemmer und Sirolimus: Wirkmechanismen und Anwendung in der Dermatologie. Calcineurin inhibitors and sirolimus: Mechanisms of action and applications in dermatology. Zeitschrift FÃ¼r Hautkrankheiten, 2002, 77, 634-640.	0.0	0
117	Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet, The, 2001, 357, 2012-2016.	6.3	239
118	CYCLOPHILIN A: INTRACELLULAR LOCALISATION IN HUMAN KERATINOCYTES. Biochemical Society Transactions, 2000, 28, A350-A350.	1.6	0
119	Hydroxyurea in psoriasis. Clinical and Experimental Dermatology, 1999, 24, 496-497.	0.6	1
120	Up-Regulation of p21WAF1 by Phorbol Ester and Calcium in Human Keratinocytes through a Protein Kinase C-Dependent Pathway. American Journal of Pathology, 1998, 153, 39-45.	1.9	52
121	Overexpression of protein kinase C-Î± and -Î² isozymes by stromal dendritic cells in basal and squamous cell carcinoma. British Journal of Dermatology, 1997, 136, 666-673.	1.4	1
122	Necrolytic migratory erythema and zinc deficiency. British Journal of Dermatology, 1997, 136, 783-785.	1.4	25
123	Overexpression of protein kinase C-Î± and -Î² isozymes by stromal dendritic cells in basal and squamous cell carcinoma. British Journal of Dermatology, 1997, 136, 666-673.	1.4	8
124	Necrolytic migratory erythema and zinc deficiency. British Journal of Dermatology, 1997, 136, 783-785.	1.4	43
125	Down-regulation of Langerhans cell protein kinase C-Î² isoenzyme expression in inflammatory and hyperplastic dermatoses. British Journal of Dermatology, 1995, 133, 157-167.	1.4	29
126	Up-Regulation of p21WAF1/CIP1 in Psoriasis and After the Application of Irritants and Tape Stripping. Journal of Investigative Dermatology, 1995, 105, 274-279.	0.3	33

#	Article	IF	Citations
127	Dissociation of Erythema and p53 Protein Expression in Human Skin Following UVB Irradiation, and Induction of p53 Protein and mRNA Following Application of Skin Irritants. Journal of Investigative Dermatology, 1994, 103, 493-499.	0.3	59
128	Translocation and Downregulation of Protein Kinase C Isoenzymes-Î± and -Îµ by Phorbol Ester and Bryostatin-1 in Human Keratinocytes and Fibroblasts. Journal of Investigative Dermatology, 1994, 103, 364-369.	0.3	46
129	Differential Expression of Protein Kinase C Isoenzymes in Normal and Psoriatic Adult Human Skin: Reduced Expression of Protein Kinase C-Î²II in Psoriasis. Journal of Investigative Dermatology, 1993, 101, 553-559.	0.3	81
130	Hydrallazine predisposes to acute cutaneous vasculitis following urography with iopamidol. British Journal of Dermatology, 1993, 129, 82-85.	1.4	22
131	Folliculitis in Down's syndrome. British Journal of Dermatology, 1993, 129, 696-699.	1.4	27
132	Phosphatidic acid and phospholipase D both stimulate phosphoinositide turnover in cultured human keratinocytes. Cellular Signalling, 1993, 5, 787-794.	1.7	20
133	CD1 gene expression in human skin. Journal of Dermatological Science, 1993, 6, 206-213.	1.0	20
134	Erythema multiform during danazol therapy. Clinical and Experimental Dermatology, 1992, 17, 140-140.	0.6	5
135	Effect of oral isotretinoin therapy on saliva volume and composition. British Journal of Dermatology, 1991, 125, 189-190.	1.4	5
136	(18) Stritnmer dermatitis. British Journal of Dermatology, 1990, 123, 63-64.	1.4	1
137	(8) Limb hypertrophy: associated with a solitary plexiform neurofibroma?. British Journal of Dermatology, 1990, 123, 89-92.	1.4	0
138	(12) Differentiation between pseudolymphoma and malignant B-cell lymphoma of the skin. British Journal of Dermatology, 1990, 123, 95-99.	1.4	0
139	(15) Erythema nodosum and cutaneous vasculitis associated with recurrence of Hodgkin's disease. British Journal of Dermatology, 1990, 123, 101-102.	1.4	6
140	Oral albendazole for the treatment of cutaneous larva migrans. British Journal of Dermatology, 1990, 122, 99-101.	1.4	61
141	Exfoliative dermatitis due to nifedipine. British Journal of Dermatology, 1989, 121, 401-404.	1.4	25
142	Darkening of white hair in Parkinson's disease. Clinical and Experimental Dermatology, 1989, 14, 317-318.	0.6	30
143	Cutaneous reaction to diltiazem resulting in an exacerbation of angina. Clinical and Experimental Dermatology, 1989, 14, 457-458.	0.6	9